Prolia 60 mg Alternative – Denosis (Denosumab) 60 mg Injection | Incepta Pharmaceuticals
Denosis 60 mg (Denosumab) Injection is listed in the supplied Lucent price catalogue attributed to Incepta Pharmaceuticals Ltd. Reference brand: Prolia (Amgen).
Pack: 1 prefilled syringe. Prescription medicine. Verify the exact manufacturer label and regulatory status; reference-brand comparison does not establish interchangeability.
Product Overview
Denosis 60 mg is listed in the supplied Lucent product catalogue. Its proposed active ingredient is Denosumab, in injection form. The manufacturer’s product labeling should be consulted for the final specification.
Denosis vs Prolia – Reference Brand Comparison
Prolia is a recognized reference brand associated with Amgen. Denosis is listed on the supplied Lucent products price sheet, attributed by the customer to Incepta Pharmaceuticals Ltd. Matching an active ingredient does not demonstrate bioequivalence, regulatory approval or permission to substitute. Biologic products require particular attention to product-specific authorization, handling and interchangeability.
Composition and Product Details
- Listed brand: Denosis
- Generic: Denosumab
- Strength: 60 mg
- Dosage form: Injection
- Catalogue pack: 1 prefilled syringe
- Attributed manufacturer: Incepta Pharmaceuticals Ltd., Bangladesh
Therapeutic Uses and Indications
Denosumab is used in osteoporosis-related bone protection for the 60 mg formulation, or prevention of skeletal-related events in selected oncology settings for the 120 mg formulation; these presentations have different approved uses. These are generic-medicine contexts, not independently confirmed approvals for this particular branded presentation. Exact eligible conditions, biomarkers and combination therapies must be confirmed from the local authorized label.
Mechanism of Action
Denosumab binds RANKL and reduces osteoclast-mediated bone resorption. Individual treatment response depends on the disease, formulation, dosing and patient factors.
Dosage and Administration
The stated 60 mg refers to the strength of the supplied product, not a recommended daily or treatment dose. Administration schedules, preparation, food instructions and monitoring depend on the approved indication and formulation. Parenteral administration must follow the official preparation and administration protocol under trained healthcare supervision. Never change strength or substitute a brand without medical advice.
Contraindications
Contraindications can include hypersensitivity and other medicine-specific conditions. Review the current prescribing information for all absolute restrictions, including relevant pregnancy-related contraindications.
Warnings and Precautions
Potential serious risks and monitoring requirements vary by medicine. Discuss infections, cardiovascular disease, liver and kidney function, other medications and pregnancy plans with the specialist. The official product leaflet determines the required safety monitoring.
Possible Side Effects
Adverse reactions may involve gastrointestinal symptoms, fatigue, laboratory abnormalities, infections or organ-specific toxicity, depending on the active ingredient. The full medicine-specific adverse effect profile, frequency and emergency warning signs must be reviewed in the authorized prescribing information.
Drug Interactions
Prescription drugs, nonprescription medicines, herbal products and some foods may interact with Denosumab. A pharmacist or specialist should review all current medicines before treatment.
Pregnancy and Breastfeeding
Some treatments can cause fetal harm or require interruption of breastfeeding. Consult the product-specific label and treating specialist for pregnancy testing, contraception and breastfeeding guidance.
Storage and Handling
Follow the temperature, light protection, cold-chain and handling requirements printed on the actual pack. Do not assume storage conditions from another brand or formulation.
Why Is Denosis Listed as an Alternative to Prolia?
The comparison is provided for product discovery by active ingredient and reference brand. It does not establish pharmaceutical or therapeutic equivalence, biosimilarity, interchangeability or authorization in any country.
Manufacturer Information
Listed manufacturer: Incepta Pharmaceuticals Ltd., Bangladesh
Reference brand: Prolia
Reference company: Amgen
Generic: Denosumab
Strength: 60 mg
Pack: 1 prefilled syringe
Frequently Asked Questions
What does Denosis contain?
Denosumab 60 mg, subject to confirmation against the official brand-specific label.
Is Denosis the same as Prolia?
No automatic equivalence or interchangeability can be inferred from the generic ingredient alone.
Can I use another strength instead?
Only when an authorized clinician specifically directs it.
Is a prescription required?
Yes. Appropriate prescription and specialist supervision are required.
Important Medical Disclaimer
Educational product identification only. Clinical information and product availability require verification against official labeling and destination-country regulatory requirements. No purchase or treatment decision should be based on this page alone.
| Generic Name | Denosumab |
|---|---|
| Strength | 60 mg |
| Manufacturer | Incepta Pharmaceuticals Ltd. |
| Pack Size | 1 prefilled syringe |
Related products
Doptelet 20 mg Alternative – Avapag (Avatrombopag) 20 mg Tablet | Everest Pharmaceuticals
Avapag 20 mg (Avatrombopag) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Doptelet (Sobi / Dova). It belongs to the thrombopoietin receptor agonist class and is used in selected thrombocytopenia associated with chronic liver disease procedures or immune thrombocytopenia.
Active ingredient: Avatrombopag
Strength: 20 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Evrenzo 50 mg Alternative – Renofix (Roxadustat) 50 mg Tablet | Everest Pharmaceuticals
Renofix 50 mg (Roxadustat) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Evrenzo (Astellas). It belongs to the HIF-prolyl hydroxylase inhibitor class and is used in anemia associated with chronic kidney disease in jurisdictions where authorized.
Active ingredient: Roxadustat
Strength: 50 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Evrenzo 70 mg Alternative – Renofix (Roxadustat) 70 mg Tablet | Everest Pharmaceuticals
Renofix 70 mg (Roxadustat) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Evrenzo (Astellas). It belongs to the HIF-prolyl hydroxylase inhibitor class and is used in anemia associated with chronic kidney disease in jurisdictions where authorized.
Active ingredient: Roxadustat
Strength: 70 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Megace 160 mg Alternative – Mezoxia (Megestrol acetate) 160 mg Tablet | Everest Pharmaceuticals
Mezoxia 160 mg (Megestrol acetate) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Megace (Bristol Myers Squibb). It belongs to the progestin class and is used in certain hormone-responsive cancer settings depending on formulation and jurisdiction.
Active ingredient: Megestrol acetate
Strength: 160 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Ofev 100 mg Alternative – Ninacent (Nintedanib) 100 mg Capsule | Incepta Pharmaceuticals
Ninacent 100 mg (Nintedanib) Capsule is listed in the supplied Lucent price catalogue attributed to Incepta Pharmaceuticals Ltd. Reference brand: Ofev (Boehringer Ingelheim).
Pack: 10 capsules. Prescription medicine. Verify the exact manufacturer label and regulatory status; reference-brand comparison does not establish interchangeability.
Ofev 150 mg Alternative – Ninacent (Nintedanib) 150 mg Capsule | Incepta Pharmaceuticals
Ninacent 150 mg (Nintedanib) Capsule is listed in the supplied Lucent price catalogue attributed to Incepta Pharmaceuticals Ltd. Reference brand: Ofev (Boehringer Ingelheim).
Pack: 10 capsules. Prescription medicine. Verify the exact manufacturer label and regulatory status; reference-brand comparison does not establish interchangeability.
Promacta / Revolade 25 mg Alternative – Elopag (Eltrombopag) 25 mg Tablet | Everest Pharmaceuticals
Elopag 25 mg (Eltrombopag) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Promacta / Revolade (Novartis). It belongs to the thrombopoietin receptor agonist class and is used in selected immune thrombocytopenia and aplastic anemia settings.
Active ingredient: Eltrombopag
Strength: 25 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Promacta / Revolade 50 mg Alternative – Elopag (Eltrombopag) 50 mg Tablet | Everest Pharmaceuticals
Elopag 50 mg (Eltrombopag) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Promacta / Revolade (Novartis). It belongs to the thrombopoietin receptor agonist class and is used in selected immune thrombocytopenia and aplastic anemia settings.
Active ingredient: Eltrombopag
Strength: 50 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.

Reviews
There are no reviews yet.